Arvinas
-$0.44 (-1.07%) Today
$0.00 (0.00%) As of 8:00 PM UTC after-hours
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.
About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
CEO
John G. Houston
Employees
280
Headquarters
New Haven, Connecticut
Founded
2013
ARVN Key Statistics
Market cap
2.17B
Price-Earnings ratio
—
Dividend yield
—
Average volume
468.47K
High today
$41.50
Low today
$39.98
Open price
$41.00
Volume
409.70K
52 Week high
$108.47
52 Week low
$37.41
ARVN News
Analyst ratings
95%
of 20 ratings
Buy
95%
Hold
5%
Sell
0%
ARVN Earnings
-$1.20
-$0.03
$1.13
$2.30
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 4, Pre-Market